PAREXEL TO OFFER RESEARCH GRANT AT 13TH BIENNIAL INTERNATIONAL PHARMACO EEG SOCIETY SYMPOSIUM
BOSTON, MA, May 10, 2004 — PAREXEL International Corporation (Nasdaq: PRXL) is again pleased to offer a Research Grant in memory of Professor Werner M. Herrmann, M.D. The Grant will be awarded to the best poster or communication contributed by a young researcher at the 13th Biennial International Pharmaco EEG Society Symposium (IPEG), September 10-12, 2004 at the Flanders Congress and Concert Center in Antwerp, Belgium.
The IPEG Symposium is a major forum for promoting developments in the methodology and application of neurophysiological research in neuropsychopharmacology. The 5,000€ grant was established in 2002 and awarded for the first time to encourage research in the field of neuropsychophysiology. A panel of judges comprised of Bernd Saletu, IPEG President, Pim Drinkenburg, IPEG Congress Chairperson, and Marc Jobert, Ph.D., Corporate Vice President, Worldwide Information Systems will officiate. Dr. Jobert will present the Grant to this year’s recipient during the closing session.
"Throughout his distinguished career, Werner was committed to the study of scientific disciplines of brain and behavior to further research in electrophysiological brain research in preclinical and clinical pharmacology, neurotoxicology and related areas of interest," stated Josef H. von Rickenbach, Chairman and Chief Executive Officer. "It is in Werner’s honor that we make this commitment to the field of neuropsychophysiology by awarding this grant bi-annually to young researchers."
PAREXEL is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. The technology portfolio includes web-based portal solutions and tracking tools, Interactive Voice Response Systems (IVRS), Clinical Trial Management Systems (CTMS), electronic diary and investigator database solutions. Perceptive also offers advanced medical diagnostics services to assess rapidly and objectively the safety and efficacy of new drugs, biologics, and medical devices in clinical trials. PAREXEL’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 52 locations throughout 36 countries around the world, and has 5,015 employees.
This release contains "forward-looking" statements regarding future results and events, including, the guidance provided by the Company with respect to the full Fiscal Year 2004 and Calendar 2004. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", "estimates", "projects" and similar expressions are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2003 as filed with the SEC on February 10, 2004, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc.